--iTeos Therapeutics and GlaxoSmithKline plc today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a ...

GSK paid iTeos $625 million in guaranteed cash, and promised up to $1.45 billion more, for rights to belrestotug.

(Reuters) -Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therapeutics Inc to develop and sell a potential cancer treatment together, the companies said on Monday.

GSK and iTeos will share in the work and the expenses for global development of EOS-448, according to the agreement. They’ll also share in commercializing the drug—if it’s approved.

GlaxoSmithKline (GSK) and iTeos Therapeutics announced on June 14, 2021 that they have signed an agreement to co-develop and co-commercialize EOS-448, an anti-T-cell immunoreceptor with immunoglobulin ...

GlaxoSmithKline GSK announced an agreement to acquire joint development and commercialization rights to iTeos Therapeutics’ ITOS early-stage cancer candidate, EOS-448, an anti-TIGIT monoclonal ...

GSK and iTeos plan to start combination studies of EOS-448 with dostarlimab in 2022. GSK’608 (anti-CD96 being developed in collaboration with 23andMe) is in phase I as monotherapy and in ...

Boston-based iTeos, whose shares jumped 52% in premarket trading, will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development ...

iTeos to receive a $625 million upfront payment in addition to potential milestones, and royalty payments on ex-US sales GSK and iTeos will co-commercialise and share profits in the US ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and iTeos Therapeutics (NASD: ITOS) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I ...